9 news items
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
AKAM
RVNC
10 May 24
. Mizuho analyst Vamil Divan maintained a Neutral rating.
Read More: Top 2 Materials Stocks That Could Blast Off This Quarter
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
RVNC
9 May 24
and the timing of events to differ materially from our expectations. These risks and uncertainties relate to, but are not limited to: our ability to obtain
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
RVNC
9 May 24
materially from our expectations. These risks and uncertainties relate to, but are not limited to: our ability to obtain funding for our operations
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
that could cause actual results and the timing of events to differ materially from our expectations. These risks and uncertainties relate
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RVNC
27 Mar 24
.
The Compensation Committee of Revance's Board of Directors approved the awards as an inducement material to the new employees
rivlnvljc1j8h9javyrtuma29th77ogeb3sj59ppaxaycwrhk
AADI
AIMD
AKRO
4 Mar 24
after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from
iqb 01e38m4vuhzigdkakinjgsdgua1snwu8dlhqqiz8tc6icgcahyk48c6
ACMR
ADSE
BYND
4 Mar 24
. (NASDAQ:NYCB) declined 13.6% to $3.0650 after the company announced that it identified material weaknesses in its
2vbrgk7u c34cfdw584
RVNC
4 Mar 24
, uncertainties and other important factors. Actual results or developments may differ materially from those projected or implied in these forward-looking
nsbra5nx3n8 th
RVNC
4 Mar 24
and involve risks, uncertainties and other important factors. Actual results or developments may differ materially from those projected or implied
- Prev
- 1
- Next